Nephrectomy after complete response to immunotherapy
A retrospective study looked at the clinical and surgical outcomes [...]
Atezolizumab and bevacizumab in patients with advanced non-clear cell renal cell carcinoma
Dr Rana McKay from University of California in San Diego, [...]
Selecting therapy for poor-risk advanced kidney cancer
In this video interview, Dr Earle Burgess from the Levine [...]
Monitoring treatment toxicities in patients with renal cell carcinoma
Drs Dan George and Tian Zhang from the Duke Prostate [...]
Real-world clinical outcomes with first-line sunitinib for metastatic kidney cancer
A paper published in The Oncologist last month analysed real-world [...]
Prognosis of type 1 and type 2 papillary renal cell carcinoma
In a recent analysis of a large database, researchers compared [...]
A potential biomarker for survival for non-metastatic kidney cancer
A recent study published in the journal International Urology and [...]
Long-term risk of recurrence after surgery for kidney cancer
A recent study published in the journal European Urology investigated [...]
Lenvatinib plus pembrolizumab shows promise in solid tumours
The combination of lenvatinib plus pembrolizumab has shown promise in [...]
Tivozanib has a better safety profile than other TKIs for the treatment of kidney cancer
A recent literature review and network meta-analysis of phase 2/3 [...]
